UTHR United Therapeutics Corporation

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 26 February 2020 United Therapeutics Corporation Reports Fourth Quarter and Full Year 2019 Financial Results

   SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced its financial results for the fourth quarter and year ended December 31,

2. 25 February 2020 United Therapeutics Corporation To Present At The 40th Annual Cowen And Company Healthcare Conference

   SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer of United

3. 24 February 2020 United Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin®

   RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) and DEKA Research & Development Corp. today announced receipt of an additional 510(k)

4. 24 February 2020 United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints

   SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced that preliminary analysis indicates that the INCREASE clinical study of

5. 19 February 2020 United Therapeutics Corporation to Report Fourth Quarter and Full Year 2019 Financial Results Before the Market Opens on Wednesday, February 26, 2020

   SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that it will report its fourth quarter and full year 2019 financial results

6. 04 February 2020 United Therapeutics Defeats Preliminary Injunction Motion In Litigation With Sandoz And RareGen

   SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 4, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced that on January 29, 2020, the United States District Court for the District of New

7. 03 February 2020 United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint

   SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 3, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced topline results from the phase 2/3 DISTINCT clinical study evaluating

8. 06 January 2020 United Therapeutics Corporation To Present At The 38th Annual J.P. Morgan Healthcare Conference

   SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of

9. 29 November 2019 CollPlant Reports Third Quarter 2019 Financial Results and Provides Business Update

   REHOVOT, Israel, Nov. 29, 2019 /PRNewswire/ -- CollPlant (NASDAQ:CLGN), a regenerative medicine company, today announced financial results for the third quarter ended September 30, 2019 and provided an update on the

10. 14 November 2019 Correvio Reports Third Quarter 2019 Financial Results

    NASDAQ: CORV  TSX: CORV FDA Accepts Brinavess™ New Drug Application Advisory Committee Date Set for December 10, 2019 PDUFA Date Set for December 24, 2019 Management to Host Conference Call and Webcast Today, November

11. 30 October 2019 United Therapeutics Corporation Reports Third Quarter 2019 Financial Results

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced its financial results for the quarter ended September 30, 2019. "We are

12. 23 October 2019 United Therapeutics Corporation to Report Third Quarter 2019 Financial Results Before the Market Opens on Wednesday, October 30, 2019

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that it will report its third quarter 2019 financial results before the

13. 21 October 2019 United Therapeutics Announces FDA Approval Of Updated Label For Orenitram Reflecting Results Of FREEDOM-EV Study

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement

14. 10 October 2019 Respira Therapeutics Regains North America Rights from United Therapeutics to Phase 2 Inhaled Drug-Device Product, RT234, for Pulmonary Hypertension Indications

    ALBUQUERQUE, N.M., Oct. 10, 2019 /PRNewswire/ -- Respira Therapeutics, a clinical-stage specialty pharmaceutical company developing next-generation cardiopulmonary disease-targeted inhalation products, has regained full

15. 11 September 2019 United Therapeutics Announces FDA Acceptance Of Trevyent New Drug Application For Review

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review